Bronchitis Treatment Market - Industry Size, Share, Growth & Forecast 2027 | UnivDatos

 

The bronchitis treatment market is expected to witness a CAGR of around ~5% during the forecast period (2021–2027). Bronchitis is when the tubes that carry air to your lungs, called the bronchial tubes, get inflamed and swollen. It can be described as either acute bronchitis or chronic bronchitis. This is caused mainly due to the sedentary lifestyle, addiction to cigarette smoke and chemical pollutants. Furthermore, rapid growth of the geriatric population and significant rise in respiratory disorders such as asthma, and lung cancer, among others is expected to drive the demand for effective bronchitis treatment. For instance, according to the World Population Ageing Report 2019 by United Nations (UN), In 2019, there were 703 million persons aged 65 years or over in the global population. This number is projected to double to 1.5 billion in 2050.

Download Free Sample of this Report - https://univdatos.com/get-a-free-sample-form-php/?product_id=21544

Due to the COVID-19 pandemic, the industry has witnessed a strong upward hike in the growth of the market. This is mainly due to the increase in covid testing during the pandemic. Additionally, Bronchitis refers to inflammation of the main airways of the lungs so patients with bronchitis may be at risk of serious illness. In addition, both bronchitis and COVID-19 affect the lungs. As per the experts from The Johns Hopkins Organization, in COVID-19-related bronchitis is an issue of an excessive amount of sputum produced in the airways, resulting in coughing and chest congestion. The sputum also narrows the airways, making breathing more difficult. The Centers for Disease Control and Prevention (CDC) also informs that the coronavirus may cause more severe illness in those with bronchitis and lung diseases. These factors are the main reasons for the market growth during the forecast period. In addition. Thus, the demand for Bronchitis treatment has increased phenomenally due to the COVID-19 pandemic.

 According to UnivDatos Market Insights (UMI)’ research report “global bronchitis treatment market”, the market is expected to witness robust growth during the forecast period 2021-2027F. Further, the major factors, such as the increasing incidence of respiratory diseases, the rising prevalence of smoking, and the rising product approvals, are driving the market.

Download Free Sample of this Report - https://univdatos.com/get-a-free-sample-form-php/?product_id=21544

Based on type, the market is classified into acute bronchitis and chronic bronchitis. Among them, in 2020, the acute category dominated the market and is expected to maintain its dominance throughout the forecast period. This is mainly due to the rising incidence of patients suffering from respiratory diseases, lung diseases, asthma, air pollution, and geriatric pollution. Additionally, the market growth is driven by the rapid growth of smoking, coupled with a rising geriatric population across the globe. In addition, breathing in air pollutants can irritate a patient’s airways and may cause shortness of breath, coughing, wheezing, asthma episodes, and chest pain. For instance, according to the world health organization (WHO), 9 out of 10 people breathe air containing high levels of pollutants. In 2019, 99% of the world population was living in places where the WHO air quality guidelines levels were not met. Both the number of cases and the prevalence of pollution have been steadily increasing over the past few decades.

Based on drug class, the market is bifurcated into antibiotics, anti-inflammatory, bronchodilators, and others. Among them, in 2020, the bronchodilator category held a significant share in the market. Bronchodilators are drugs often used as aerosols to widen the air passages by relaxing the bronchial muscle. They are effective in helping older, children and adults with asthma. Furthermore, asthmatic bronchitis is an inflammatory condition that causes airways to narrow. For instance, according to the world health organization (WHO), Asthma affected an estimated 262 million people in 2019 and caused 455,000 deaths.

For more informative information, please visit us – https://univdatos.com/report/bronchitis-treatment-market/

Based on distribution channel, the market is bifurcated into hospital hospitals pharmacies, retail pharmacies, and others. In 2020, the hospital pharmacies accounted for the majority share during the forecast period owing to the increasing construction of hospitals, the large number of patients treated at hospitals, the availability of trained professionals, and a surge in the number of respiratory cases, in the hospital setting. According to, institute for Health Metrics and Evaluation (IHME), Chronic respiratory diseases were responsible for 71·1 million YLLs and 32·4 million YLDs in 2019. Chronic obstructive pulmonary disease (COPD) and asthma were the two largest contributors to the global respiratory disease burden.

North America to witness extensive growth

For a better understanding of the market adoption of the Bronchitis treatment industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America); Europe (Germany, United Kingdom, France, Spain, Italy, Rest of Europe); Asia-Pacific (China, Japan, India, Rest of Asia-Pacific); and the Rest of World. In 2020. North America held an extensive market share owing to the rising prevalence of bronchitis, awareness, and well-established medical infrastructure and facilities. In addition, increasing environmental pollution, rising geriatric population with various respiratory diseases, and growing prevalence of lung diseases. Additionally, growth in the number of people addicted to smoking will drive the market growth in this region.  According to World Population Ageing, in 2019, the elderly population of North America was 59.9 million which is expected to reach 96.2 million by 2050.

For more informative information, please visit us – https://univdatos.com/report/bronchitis-treatment-market/

According to UnivDatos Market Insights (UMI)’, the key players with a considerable market share in the global bronchitis treatment market are AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Dr. Reddy's Laboratories Ltd, Sanofi SA, Boehringer Ingelheim International GmbH, Pfizer Inc., Melinta Therapeutics, Lupin Limited, Cadila Healthcare Limited.

“Global bronchitis treatment Market” provides comprehensive qualitative and quantitative insights on the industry potential, key factors impacting sales and purchase decisions, hotspots, and opportunities available for the market players. Moreover, the report also encompasses the key strategic imperatives for success for competitors along with strategic factorial indexing measuring competitors’ capabilities on different parameters. This will help companies in the formulation of go-to-market strategies and identifying the blue ocean for its offerings.      

Market Segmentation:

1.     By Type (Acute Bronchitis, Chronic Bronchitis)

2.     By Drug Class (Antibiotics, Anti-inflammatory Drugs, Bronchodilator, Other Drugs)

3.     By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)

4.     By Region (North America, Europe, Asia-Pacific, Rest of the World)

5.     By Company (AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Dr. Reddy's Laboratories Ltd, Sanofi SA, Boehringer Ingelheim International GmbH, Pfizer Inc., Melinta Therapeutics, Lupin Limited, Cadila Healthcare Limited.)

Key questions answered in the study:

1.     What are the current and future trends of the global bronchitis treatment industry?

2.     How the industry has been evolving in terms of type, distribution channel, and application?

3.     How the competition has been shaping across the countries followed by their comparative factorial indexing?

4.     What are the key growth drivers and challenges for the global bronchitis treatment industry?

5.     What is the customer orientation, purchase behavior, and expectations from the global bronchitis treatment suppliers across various region and countries? 

Table of Content –

1 MARKET INTRODUCTION

2 RESEARCH METHODOLOGY OR ASSUMPTION

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 BRONCHITIS TREATMENT MARKET COVID-19 IMPACT

6 BRONCHITIS TREATMENT MARKET REVENUE (USD BN), 2019-2027F

7 MARKET INSIGHTS BY TYPE

8 MARKET INSIGHTS DRUG CLASS

9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

10 MARKET INSIGHTS BY REGION

11 BRONCHITIS TREATMENT MARKET DYNAMICS

12 BRONCHITIS TREATMENT MARKET OPPORTUNITIES

13 BRONCHITIS TREATMENT MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

15 VALUE CHAIN ANALYSIS

16 COMPETITIVE SCENARIO

17 COMPANY PROFILED

18 DISCLAIMER

Browse Other Related Research Reports from UnivDatos Market Insights

·       Oncology Therapeutics Market to exceed US$ 247.5 Billion by 2027 Globally |CAGR: 8.2%|

·       Neuromodulation Devices Market to exceed US$ 11.7 Billion by 2027 Globally |CAGR: 8.4%| 

·       Digital Health Market to exceed US$ 746 Billion by 2027 Globally | CAGR: 26.3% |

·       Heart Pump Devices Market to exceed US$ 6 Billion by 2027 Globally | CAGR: 18.9% |